Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Phase 2 × Adenocarcinoma × paricalcitol × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pancreatic Neoplasms 3 Prostatic Neoplasms 1 Neoplasm Metastasis 1 Myelodysplastic Syndromes 1 Leukemia, Myelomonocytic, Chronic 1 Leukemia 1 Anemia, Refractory, with Excess of Blasts 1 Anemia, Refractory 1 Adenocarcinoma 1

Interventions

Oxaliplatin 26 Gemcitabine 21 Fluorouracil 17 Capecitabine 16 Leucovorin 15 pembrolizumab 13 Cisplatin 13 Docetaxel 12 Bevacizumab 12 Radiotherapy 8 Paclitaxel 7 Irinotecan 7 Trastuzumab 6 Pemetrexed 6 Carboplatin 6 130-nm albumin-bound paclitaxel 6 durvalumab 5 cemiplimab 5 Sunitinib 4 Metformin 4 trastuzumab deruxtecan 3 tislelizumab 3 cabozantinib 3 atezolizumab 3 Taxes 3 Sorafenib 3 Ramucirumab 3 Gefitinib 3 Folfox protocol 3 Everolimus 3

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03415854 2023-12-15

NABPLAGEMD

HonorHealth Research Institute

Phase 2 Completed

Gastrointestinal

Adenocarcinoma, Pancreatic Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡